PRS50 Defining Type 2 Asthma and Patients Eligible to Dupilumab in Italy: A Biomarker-Based Analysis

Saved in:
Bibliographic Details
Published in:Value in health Vol. 23; p. S726
Main Authors: Canonica, G.W., Blasi, F., Crimi, N., Paggiaro, P., Papi, A., Fanelli, F., Stassaldi, A., Serra, A., Furneri, G.
Format: Journal Article
Language:English
Published: Elsevier Inc 01.12.2020
Subjects:
Internal Medicine
ISSN:1098-3015, 1524-4733
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Author Blasi, F.
Fanelli, F.
Stassaldi, A.
Serra, A.
Furneri, G.
Canonica, G.W.
Crimi, N.
Paggiaro, P.
Papi, A.
Author_xml – sequence: 1
  givenname: G.W.
  surname: Canonica
  fullname: Canonica, G.W.
  organization: Humanitas University, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
– sequence: 2
  givenname: F.
  surname: Blasi
  fullname: Blasi, F.
  organization: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and University of Milan, Milan, Italy
– sequence: 3
  givenname: N.
  surname: Crimi
  fullname: Crimi, N.
  organization: A.O.U. "Policlinico-Vittorio Emanuele", Catania, Italy
– sequence: 4
  givenname: P.
  surname: Paggiaro
  fullname: Paggiaro, P.
  organization: Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
– sequence: 5
  givenname: A.
  surname: Papi
  fullname: Papi, A.
  organization: University of Ferrara, Ferrara, Italy
– sequence: 6
  givenname: F.
  surname: Fanelli
  fullname: Fanelli, F.
  organization: Sanofi SpA, Milan, Italy
– sequence: 7
  givenname: A.
  surname: Stassaldi
  fullname: Stassaldi, A.
  organization: Sanofi SpA, Milan, Italy
– sequence: 8
  givenname: A.
  surname: Serra
  fullname: Serra, A.
  organization: Sanofi SpA, Milan, Italy
– sequence: 9
  givenname: G.
  surname: Furneri
  fullname: Furneri, G.
  organization: EBMA Consulting SRL, Melegnano, Italy
BookMark eNqFkd1KAzEQhYNUUKtP4E1eYNdJstkfRaG1_oGg2Hod0mS2Zt3uls1W6NubpV4J4tUMDOfMzHdOyKhpGyTknEHMgKUXVVx96TrmwCGGPGaFgANyzCRPoiQTYhR6KPJIAJNH5MT7CgBSweUxsa9vcwl0hqVrXLOii90GKacT33-sNdWNpa-6d9j0nt7VbuWWNdK-pbPtxtXbtV5S19CnXte7SzqhU9eudfeJXTTVHi2dNGHgnT8lh6WuPZ791DF5v79b3D5Gzy8PT7eT58hwCRBlRlvLpBHMLosMdQKGa5SFFZlkjCeiNGkpwKZWc4lFLk3G8yzjUEBZ6GUqxkTsfU3Xet9hqTadCxftFAM1gFKVGkCpAZSCXA2ggup6r8Jw2pfDTnkTPjZoXYemV7Z1_-hvfulNHWAaXX_iDn3VbrvAwSumPFeg5kMUQxIcRMLyVASDq78N_l3_DScumto
ContentType Journal Article
Copyright 2020
Copyright_xml – notice: 2020
DBID 6I.
AAFTH
AAYXX
CITATION
DOI 10.1016/j.jval.2020.08.1930
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
DatabaseTitle CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1524-4733
EndPage S726
ExternalDocumentID 10_1016_j_jval_2020_08_1930
S1098301520341863
1_s2_0_S1098301520341863
GroupedDBID ---
--K
--M
.1-
.3N
.FO
.GA
.Y3
.~1
0R~
10A
123
1OC
1P~
1~.
29Q
31~
36B
4.4
44B
457
4G.
51W
51X
52N
52P
52R
52S
52X
53G
5LA
5VS
66C
6PF
7-5
7PT
8-1
8P~
8UM
AAEDT
AAEDW
AAFJI
AAFWJ
AAIKJ
AAKOC
AALRI
AAMMB
AAOAW
AAPFB
AAQFI
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYWO
ABBQC
ABCQN
ABDBF
ABEML
ABIVO
ABJNI
ABMAC
ABMMH
ABMZM
ABWVN
ABXDB
ACDAQ
ACGFS
ACHQT
ACIEU
ACLOT
ACPRK
ACRLP
ACRPL
ACUHS
ACVFH
ACXQS
ADBBV
ADCNI
ADEZE
ADFHU
ADMUD
ADNMO
ADVLN
AEBSH
AEFGJ
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AEXQZ
AEYQN
AFBPY
AFEBI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AFZJQ
AGHFR
AGQPQ
AGTHC
AGUBO
AGXDD
AGYEJ
AIDQK
AIDYY
AIEXJ
AIGII
AIIAU
AIIUN
AIKHN
AITUG
AJAOE
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
AOMHK
APXCP
ASPBG
AVARZ
AVWKF
AXJTR
AXLSJ
AZFZN
BAWUL
BFHJK
BKOJK
BLXMC
BNPGV
BY8
CAG
CO8
COF
CS3
DCZOG
DIK
DU5
EAD
EAP
EBS
EFJIC
EFKBS
EFLBG
EJD
EMB
EMK
EMOBN
ESX
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
GBLVA
HF~
HVGLF
HZI
HZ~
IHE
IXB
KOM
LH4
M41
MO0
N9A
O-L
O9-
OAUVE
OIG
OK1
OVD
P-8
P-9
P2P
PC.
PQQKQ
PRBVW
Q38
QB0
R2-
ROL
SDF
SEL
SES
SPCBC
SSB
SSF
SSH
SSO
SSZ
SV3
T5K
TEORI
TUS
W99
WIN
WYUIH
XG1
YFH
Z5R
~G-
~HD
0SF
6I.
AACTN
AAFTH
AAHHS
ABVKL
ACCFJ
AEEZP
AEQDE
AFCTW
AFKWA
AIWBW
AJBDE
AJOXV
AMFUW
NCXOZ
RIG
SUPJJ
AAIAV
ABLVK
ABYKQ
AJBFU
AKYCK
IXIXF
LCYCR
AAYXX
ALUQN
CITATION
O8X
ID FETCH-LOGICAL-c2500-7cadd15c31db97ea40c2ae59d37511243fc6f30d6da25e985c728772090f9ab63
ISSN 1098-3015
IngestDate Sat Nov 29 07:03:07 EST 2025
Fri Feb 23 02:40:15 EST 2024
Sun Feb 23 10:18:50 EST 2025
Tue Oct 14 19:30:46 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License http://www.elsevier.com/open-access/userlicense/1.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c2500-7cadd15c31db97ea40c2ae59d37511243fc6f30d6da25e985c728772090f9ab63
OpenAccessLink https://dx.doi.org/10.1016/j.jval.2020.08.1930
ParticipantIDs crossref_primary_10_1016_j_jval_2020_08_1930
elsevier_sciencedirect_doi_10_1016_j_jval_2020_08_1930
elsevier_clinicalkeyesjournals_1_s2_0_S1098301520341863
elsevier_clinicalkey_doi_10_1016_j_jval_2020_08_1930
PublicationCentury 2000
PublicationDate December 2020
PublicationDateYYYYMMDD 2020-12-01
PublicationDate_xml – month: 12
  year: 2020
  text: December 2020
PublicationDecade 2020
PublicationTitle Value in health
PublicationYear 2020
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
SSID ssj0006325
Score 2.2802417
SourceID crossref
elsevier
SourceType Index Database
Publisher
StartPage S726
SubjectTerms Internal Medicine
Title PRS50 Defining Type 2 Asthma and Patients Eligible to Dupilumab in Italy: A Biomarker-Based Analysis
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1098301520341863
https://www.clinicalkey.es/playcontent/1-s2.0-S1098301520341863
https://dx.doi.org/10.1016/j.jval.2020.08.1930
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection Journals 2021
  customDbUrl:
  eissn: 1524-4733
  dateEnd: 20201231
  omitProxy: false
  ssIdentifier: ssj0006325
  issn: 1098-3015
  databaseCode: AIEXJ
  dateStart: 20191101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1db9MwFLXKhhAvCAaI8iU_oL3QVInjxAlvHQwYgqmiZfTNchK7pNqyqmmn9Rfwt7mO46SsE18SL1Hryo2Ve3LvsX3PNUIvlKeEJEHiuDSJHCpT5cQBTRwvIUpGmiNUpyicfGTHx9FkEg87ne9WC3NxyooiuryM5__V1NAGxtbS2b8wd_On0ACfwehwBbPD9Y8MP_w8ClzwI6o6-uHl2KyxDsrltzNhtAGmlGqpU7qmuVZOAf98s5rn4KdEohdAjoCRr41m_SA_P9MZPAvnAOJd1hQx2SS1J-J0VdUeMaLKdluj0HV3K3b6rv-138z8tXKzIs1NU3W4mBF-tXta02kujApn2N9cnCBXEz0a1cxPSZ2ermEKjsXsZsva8RLqUGaKYljPTPwN1zpiJNwI0_brVggwqxGz_gxM19dj0iVagaa6bcRr8hBHeih6JMSFaB6F_g20S1gQg3vcHRwdTj40QT30q_N7m6HbAlZVquDWra4nORvEZXwX3alnHHhgkHIPdWSxh259qnMq9tD-0FQvX_fwuBXjlT28j4dtXfP1fZRVyMIWWVgjCxNskIUBWdgiC1tk4eU5bpCF8wJXyHqFB_gKrrDF1QP05e3h-PV7pz6kw0mBPbsOSyFCekHqe1kSMymomxIhgzjzmeby1FdpqHw3CzNBAhlHQcpgks6IG7sqFknoP0Q7gEb5CGEV6l8pY4lSNPOYoFmiT7USaeSFLI27qGefKp-bWizcJinOuDYC10bgbsS1EbqI2ifPrcwYAiMHoPy6G7uumyzrd7zkHi8Jd_kWeLoobHrW_NXw0t_d8vG_dnyCbrdv3VO0s1ys5DN0M71Y5uXieY3hH4r9uSw
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PRS50+Defining+Type+2+Asthma+and+Patients+Eligible+to+Dupilumab+in+Italy%3A+A+Biomarker-Based+Analysis&rft.jtitle=Value+in+health&rft.au=Canonica%2C+G.W.&rft.au=Blasi%2C+F.&rft.au=Crimi%2C+N.&rft.au=Paggiaro%2C+P.&rft.date=2020-12-01&rft.pub=Elsevier+Inc&rft.issn=1098-3015&rft.eissn=1524-4733&rft.volume=23&rft.spage=S726&rft.epage=S726&rft_id=info:doi/10.1016%2Fj.jval.2020.08.1930&rft.externalDocID=S1098301520341863
thumbnail_m http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F10983015%2FS1098301520X00155%2Fcov150h.gif